Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 17/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL28532491 | 0.89 | EGLN2 (0.43) | EGLN2CYP11B2PDE10A | |
| SCHEMBL21807360 | 0.79 | AHR (0.54) | EGLN2CYP11B2PDE10ANPC1RAB9A | |
| SCHEMBL543601 | 0.79 | EGLN2 (0.47) | EGLN2CYP11B2PDE10A | |
| SCHEMBL30485242 | 0.79 | CYP11B2 (0.45) | CYP11B2PDE10ANPC1RAB9A | |
| SCHEMBL13390440 | 0.79 | CYP11B2 (0.53) | CYP11B2PDE10ANPC1RAB9A | |
| SCHEMBL13218425 | 0.79 | CYP11B2 (0.45) | CYP11B2PDE10AKDM4E | |
| SCHEMBL3300546 | 0.79 | NUDT1 (0.57) | EGLN2CYP11B2PDE10AKDM4E | |
| SCHEMBL19658704 | 0.76 | EGLN2 (0.45) | EGLN2CYP11B2PDE10A | |
| SCHEMBL2036746 | 0.76 | PDE10A (0.49) | CYP11B2PDE10A | |
| SCHEMBL19659205 | 0.76 | EGLN2 (0.45) | EGLN2CYP11B2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3889152-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| US-20210070754-A1 | JAK INHIBITOR AND USE THEREOF | ZHUHAI UNITED LABORATORIES CO., LTD. (CN) | 2021-03-11 | — | — | US | disclosed |
| WO-2020108613-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2020-06-04 | — | — | WO | disclosed |
| WO-2019149244-A1 | JAK INHIBITOR AND USE THEREOF | 南京明德新药研发股份有限公司 | 2019-08-08 | — | — | WO | disclosed |
| US-20180179209-A1 | JAK INHIBITORS | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-06-28 | — | — | US | disclosed |
| US-20180179209-A1 | JAK INHIBITORS | Wuxi Fortune Pharmaceutical Co., Ltd (CN) | 2018-06-28 | — | — | US | disclosed |
| US-9994590-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | CELON PHARMA S.A. (PL) | 2017-04-27 | — | — | US | disclosed |
| US-9592230-B2 | Substituted imidazoles as PDE10A inhibitors | H. LUNDBECK A/S (DK) | 2017-03-14 | — | — | US | disclosed |
| US-20170037060-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2017-02-09 | — | — | US | disclosed |
| US-20150322090-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150190395-A1 | Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors | H. LUNDBECK A/S (DK) | 2015-07-09 | — | — | US | disclosed |
| US-9018217-B2 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-04-28 | — | — | US | disclosed |
| US-20150025081-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2015-01-22 | — | — | US | disclosed |
| US-8865711-B2 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2014-10-21 | — | — | US | disclosed |
| US-8431593-B2 | Heteroaryl amide derivatives | H. LUNDBECK A/S (DK) | 2013-04-30 | — | — | US | disclosed |
| US-20120135987-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-05-31 | — | — | US | disclosed |
| US-8133897-B2 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2012-03-13 | — | — | US | disclosed |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | H. LUNDBECK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| US-20100016303-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016303-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | EGLN2 2987/4885CYP11B2 924/4885PDE10A 1/4885 |
| US-20150322090-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | EGLN2 479/4885CYP11B2 58/4885PDE10A 2086/4885 |
| US-20180179209-A1 | JAK INHIBITORS | JAK2, JAK1, JAK3 | EGLN2 761/4885CYP11B2 2353/4885PDE10A 1057/4885 |
| US-20170114064-A1 | FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | PDE3B, PDE3A, PDE5A | EGLN2 3130/4885CYP11B2 125/4885PDE10A 7/4885 |
| US-20150190395-A1 | Novel Phenylimidazole Derivatives as PDE10A Enzyme Inhibitors | PDE10A, PDE5A, PDE3B | EGLN2 2987/4885CYP11B2 924/4885PDE10A 1/4885 |
| US-20170037060-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | EGLN2 479/4885CYP11B2 58/4885PDE10A 2086/4885 |
| US-20210070754-A1 | JAK INHIBITOR AND USE THEREOF | JAK1, JAK2, TYK2 | EGLN2 1473/4885CYP11B2 1047/4885PDE10A 1995/4885 |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | HCAR2, PIGS, GPR52 | EGLN2 616/4885CYP11B2 415/4885PDE10A 2840/4885 |
| US-20120135987-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | EGLN2 2987/4885CYP11B2 924/4885PDE10A 1/4885 |
| US-20150025081-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | EGLN2 2987/4885CYP11B2 924/4885PDE10A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.